<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181401</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT No. 2010-019347-18</org_study_id>
    <nct_id>NCT01181401</nct_id>
  </id_info>
  <brief_title>InductionChemo-Radio-Antibody-Treatment</brief_title>
  <acronym>ICRAT</acronym>
  <official_title>Randomized Phase II Study of Two Different Regimens of TPF Induction Chemotherapy Regimen Followed by Radiation Therapy Plus Cetuximab (TPF-CET-HART) vs. HART and Cis-platinum, 5-FU (PF-HART) in Patients With Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, Phase II-study to evaluate the efficacy of a standard-TPF&#xD;
      induction chemotherapy (IC) and an alternative TPF induction chemotherapy followed by&#xD;
      radio-antibody-therapy, in patients with unresectable LA-SCC of the HN region&#xD;
      (oro-hypopharynx carcinoma, cancer of the oral cavity).&#xD;
&#xD;
      The primary objective of the study is to assess the feasibility of an experimental&#xD;
      'fractionated' TPF regimen compared to a current standard TPF regimen.&#xD;
&#xD;
      Composite endpoint of compliance and feasibility in terms of&#xD;
&#xD;
        -  response (RECIST1.1) and&#xD;
&#xD;
        -  hematological acute toxicity (CTCAE v.4.02)&#xD;
&#xD;
        -  on time application of RAT following an experimental or standard TPF IC.&#xD;
&#xD;
      Secondary endpoints are&#xD;
&#xD;
        -  Treatment intensity achieved&#xD;
&#xD;
        -  Toxicity (according to CTCAE v.4.02)&#xD;
&#xD;
        -  Response rates after completion of induction chemotherapy and after completion of entire&#xD;
           protocol treatment (RECIST1.1)&#xD;
&#xD;
        -  Survival (progression-free, metastasis-free, recurrence-free, overall) 1 year after&#xD;
           randomisation&#xD;
&#xD;
        -  Quality of life according to EORTC QoL C30 &amp; HN35&#xD;
&#xD;
      The study will be conducted at 5-6 investigational sites in Germany recruiting 90 patients in&#xD;
      total. Eligible patients will have a diagnosis of histologically confirmed SSC of the HN.&#xD;
      Patients will receive one of 2 different regimens of TPF IC followed by cetuximab together&#xD;
      with radiotherapy (RAT) or a standard radiochemotherapy(RCT) regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of an experimental 'fractionated' TPF regimen compared to a current standard TPF regimen.</measure>
    <time_frame>August 2010- December 2012</time_frame>
    <description>acute hematological toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival and late morbidity</measure>
    <time_frame>1 year</time_frame>
    <description>All adequate items illustrating acute toxicity and late morbidity, in particular by hematological measures until one year after treatment (according to NCI-CTCAE v.4.02) Survival (progression-free, metastases-free, recurrence-free, Overall survival) after 1 year Response rates after TPF IC (RECIST1.1) Response rates after completion of multimodal treatment (see follow-up for scheduling RECIST1.1) Efficacy in relation to HPV status (p16 IHC) Quality of life according to EORTC QLC-30 &amp; HN35</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Squamous Cell Carcinoma of the Head</condition>
  <condition>Squamous Cell Carcinoma of the Neck</condition>
  <arm_group>
    <arm_group_label>TPF standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TPF version 1 (standard)&#xD;
Induction chemotherapy:&#xD;
Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 every 21 days for 3 cycles&#xD;
Antibody therapy with:&#xD;
cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX&#xD;
RTX: HART (72 Gy), IMRT or 3D-conformal techniques</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPF experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPF version 2 (experimental)&#xD;
Induction chemotherapy:&#xD;
Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles&#xD;
Antibody therapy with:&#xD;
cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX&#xD;
RTX: HART (72 Gy), IMRT or 3D-conformal techniques</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard RCT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard RCT:&#xD;
HART (72 Gy), IMRT or 3D-conformal techniques&#xD;
with concurrent chemotherapy: Cis-platinum 30 mg/m2 once weekly d 1, 8, 15, 22, 29, 36 5-FU 600mg/m² /24h c.i. d 1-5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPF induction chemotherapy</intervention_name>
    <description>Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 Cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX</description>
    <arm_group_label>TPF standard</arm_group_label>
    <other_name>Docetaxel (Taxotere)</other_name>
    <other_name>Cisplatin</other_name>
    <other_name>5-Flurouracil</other_name>
    <other_name>Cetuximab (Erbitux)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPF experimental</intervention_name>
    <description>Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles 2. Antibody therapy with: cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX</description>
    <arm_group_label>TPF experimental</arm_group_label>
    <other_name>Docetaxel (Taxotere)</other_name>
    <other_name>Cisplatin</other_name>
    <other_name>5-Flurouracil</other_name>
    <other_name>Certuximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard Radiochemotherapy (HART)</intervention_name>
    <description>Hyperfractionated accelerated radiotherapy with concurrent Cisplatin and 5-Fluorouracil chemotherapy</description>
    <arm_group_label>Standard RCT</arm_group_label>
    <other_name>Cis-platinum</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven unresectable SCC of the oral cavity, oropharynx and hypopharynx&#xD;
             (stage IVA &amp; IVB)&#xD;
&#xD;
          -  Written and signed informed consent&#xD;
&#xD;
          -  Karnofsky PS &gt; 70 %&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Curative treatment intent&#xD;
&#xD;
          -  Adequate bone marrow, hepatic and renal functions as evidenced by the following:&#xD;
&#xD;
        Hematology (Bone marrow):&#xD;
&#xD;
          -  Neutrophils &gt; 2.0 109/L&#xD;
&#xD;
          -  Platelets &gt; 100 x 109/L&#xD;
&#xD;
          -  Hemoglobin &gt; 10 g/dL&#xD;
&#xD;
        Hepatic function:&#xD;
&#xD;
          -  Total serum bilirubin &lt; 1 time the UNL of the participating center&#xD;
&#xD;
          -  ASAT (SGOT) and ALAT (SGPT) &lt; 2.5 x UNL&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 5 x UNL&#xD;
&#xD;
        Renal function :&#xD;
&#xD;
          -  serum creatinine (SC) &lt; 120 µmol/L (1.4 mg/dl);&#xD;
&#xD;
          -  if values are &gt; 120 µmol/L, the creatinine clearance should be &gt; 60 ml/min (actual or&#xD;
             calculated by the Cockcroft-Gault method as follows :&#xD;
&#xD;
        weight (kg) x (140 - age) --------------------------------- K x serum creatinine&#xD;
&#xD;
        serum creatinine in mg/dL: K = 72 in man K = 85 in woman serum creatinine in µmol/L: K =&#xD;
        0.814 in man K = 0.96 in woman&#xD;
&#xD;
        • If of childbearing potential, willingness to use effective contraceptive method for the&#xD;
        study duration and 2 months post-dosing.&#xD;
&#xD;
        All patients require:&#xD;
&#xD;
          -  dental examination and appropriate dental preservation if needed 1 week prior to the&#xD;
             beginning of radiotherapy,&#xD;
&#xD;
          -  gastric feeding tube and Portal-catheter.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other neoplasia within the past 5 years with the exception of a controlled skin cancer&#xD;
             or &quot;in situ&quot; cervix cancer&#xD;
&#xD;
          -  Unknown primary (CUP), nasopharynx, laryngeal or salivary gland cancer&#xD;
&#xD;
          -  Distant metastatic disease (M1)&#xD;
&#xD;
          -  Serious co-morbidity, e.g. arteriosclerosis with apoplexy, recent myocardial&#xD;
             infarction, high-grade carotid stenoses, unstable cardiac disease despite treatment,&#xD;
             congestive heart failure NYHA grade 3 and 4, insulin-dependent diabetes mellitus,&#xD;
             uncontrolled hypertension, liver cirrhosis (Quick &lt; 75%, total protein &lt;3.0 g/dl,&#xD;
             bilirubin &gt;2mg/ml) or kidney insufficiency (creatinine &gt;1.4 mg/ml, the creatinine&#xD;
             clearance should be &gt; 60 ml/min)&#xD;
&#xD;
          -  patients with ASAT or ALAT &gt; 2.5 UNL associated with alkaline phosphatase &gt; 5 UNL are&#xD;
             not eligible for the study&#xD;
&#xD;
          -  Known HIV-infection&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Women of child-bearing potential with unclear contraception&#xD;
&#xD;
          -  Previous treatment of the disease with chemotherapy, radiotherapy, EGFR-targeting&#xD;
             agents or surgery exceeding biopsy in head and neck&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs or participation in another&#xD;
             clinical trial with any investigational drug within 30 days prior to study screening&#xD;
&#xD;
          -  Social situations that limit compliance with study requirements&#xD;
&#xD;
          -  Deficient dental preservation status or not accomplished wound healing&#xD;
&#xD;
          -  Legal incapacity&#xD;
&#xD;
          -  Prior accommodation in an institution under officially or judicially orders (§ 40 1 p.&#xD;
             3 No. 4 AMG)&#xD;
&#xD;
          -  Symptomatic peripheral neuropathy National Cancer Institute-Common Toxicity Criteria&#xD;
             (NCI-CTC) grade 2 and/or ototoxicity grade 2, except if due to trauma or mechanical&#xD;
             impairment due to tumor mass&#xD;
&#xD;
          -  Known allergic/hypersensitivity reaction to any of the components of the treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Budach, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité Universitaetsmedizin Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Universitaetsmedizin Berlin, CVK, CBF</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1695-704.</citation>
    <PMID>17960012</PMID>
  </results_reference>
  <results_reference>
    <citation>Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1705-15.</citation>
    <PMID>17960013</PMID>
  </results_reference>
  <results_reference>
    <citation>Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan C, Norris CM, Lake-Willcutt B, Case MA, Costello R, Posner M. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer. 2003 Jan 15;97(2):412-8.</citation>
    <PMID>12518365</PMID>
  </results_reference>
  <results_reference>
    <citation>Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010 Jan;11(1):21-8. doi: 10.1016/S1470-2045(09)70311-0. Epub 2009 Nov 10. Erratum in: Lancet Oncol. 2010 Jan;11(1):14.</citation>
    <PMID>19897418</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 12, 2010</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <last_update_submitted>January 29, 2019</last_update_submitted>
  <last_update_submitted_qc>January 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Carmen Stromberger</investigator_full_name>
    <investigator_title>Prof. Dr. Volker Budach</investigator_title>
  </responsible_party>
  <keyword>induction chemotherapy</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>locally advanced head neck tumor</keyword>
  <keyword>toxicity</keyword>
  <keyword>LA SCCHN</keyword>
  <keyword>Unresectable squamous cell cancer of the head and neck,</keyword>
  <keyword>Stage IV (UICC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

